Interestingly, individuals with Trisomy 21, characterized by a higher incidence of early-onset AD, display a similar increase in levels of the metabolites listed above (27) as a result of inflammatory signaling involving the IFN cascade and its downstream target indole 2,3-dioxygenase (IDO1) (27). This evidence concerns the gene IDO1 and trisomy 21.